Overall response at EOT
| Response . | All treated, (N = 57) . | Efficacy evaluable, (n = 56) . |
|---|---|---|
| Objective response rate (CR + PR), n (%) | 53 (93) | 53 (95) |
| 95% CI | (83.0-98.1) | (85.1-98.9) |
| CR, n (%) | 50 (88) | 50 (89) |
| 95% CI | (76.3-94.9) | (78.1-96.0) |
| PR, n (%) | 3 (5) | 3 (5) |
| 95% CI | (1.1-14.6) | (1.1-14.9) |
| Stable disease, n (%) | 0 | 0 |
| PD, n (%) | 2 (4) | 2 (4) |
| Indeterminate response, n (%) | 1 (2) | 1 (2) |
| Not evaluable, n (%) | 1 (2) | 0 |
| Proportion of patients with a DOR∗ (mo) beyond 2 y (95% CI), % | — | 88.3 (75.7-94.6) |
| Proportion of patients with a DOCR∗ (mo) beyond 2 y (95% CI), % | — | 88.4 (76.0-94.6) |
| Response . | All treated, (N = 57) . | Efficacy evaluable, (n = 56) . |
|---|---|---|
| Objective response rate (CR + PR), n (%) | 53 (93) | 53 (95) |
| 95% CI | (83.0-98.1) | (85.1-98.9) |
| CR, n (%) | 50 (88) | 50 (89) |
| 95% CI | (76.3-94.9) | (78.1-96.0) |
| PR, n (%) | 3 (5) | 3 (5) |
| 95% CI | (1.1-14.6) | (1.1-14.9) |
| Stable disease, n (%) | 0 | 0 |
| PD, n (%) | 2 (4) | 2 (4) |
| Indeterminate response, n (%) | 1 (2) | 1 (2) |
| Not evaluable, n (%) | 1 (2) | 0 |
| Proportion of patients with a DOR∗ (mo) beyond 2 y (95% CI), % | — | 88.3 (75.7-94.6) |
| Proportion of patients with a DOCR∗ (mo) beyond 2 y (95% CI), % | — | 88.4 (76.0-94.6) |
PR, partial response.
DOR/DOCR analyses are performed in patients who achieved a PR or CR (DOR)/CR (DOCR). Data cutoff: 22 May 2023.